0001104659-23-129777.txt : 20231227 0001104659-23-129777.hdr.sgml : 20231227 20231227174113 ACCESSION NUMBER: 0001104659-23-129777 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20231226 FILED AS OF DATE: 20231227 DATE AS OF CHANGE: 20231227 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: GOODMAN JONATHAN R. CENTRAL INDEX KEY: 0001868590 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39373 FILM NUMBER: 231518935 MAIL ADDRESS: STREET 1: 4850 WEST 78TH STREET CITY: INDIANAPOLIS STATE: IN ZIP: 46268 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: POINT Biopharma Global Inc. CENTRAL INDEX KEY: 0001811764 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 850800493 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 4850 WEST 78TH STREET CITY: INDIANAPOLIS STATE: IN ZIP: 46268 BUSINESS PHONE: (317) 543-9957 MAIL ADDRESS: STREET 1: 4850 WEST 78TH STREET CITY: INDIANAPOLIS STATE: IN ZIP: 46268 FORMER COMPANY: FORMER CONFORMED NAME: Therapeutics Acquisition Corp. DATE OF NAME CHANGE: 20200511 4 1 tm2333785-7_4seq1.xml OWNERSHIP DOCUMENT X0508 4 2023-12-26 1 0001811764 POINT Biopharma Global Inc. PNT 0001868590 GOODMAN JONATHAN R. 4850 WEST 78TH STREET INDIANAPOLIS IN 46268 1 0 0 0 0 Common Stock 2023-12-26 4 U 0 41872 D 0 I Long Zone Holdings, Inc. Stock Option (Right to Buy) 6.97 2023-12-27 4 D 0 35872 D 2026-12-01 Common Stock 35872 0 D Stock Option (Right to Buy) 8.47 2023-12-27 4 D 0 25000 D 2027-07-06 Common Stock 25000 0 D Stock Option (Right to Buy) 8.31 2023-12-27 4 D 0 25614 D 2028-06-02 Common Stock 25614 0 D Stock Option (Right to Buy) 9.12 2023-12-27 4 D 0 44749 D 2029-06-01 Common Stock 44749 0 D This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of October 2, 2023, by and among POINT Biopharma Global Inc. (the "Issuer"), Eli Lilly and Company (the "Parent"), and Yosemite Falls Acquisition Corporation, a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub completed a cash tender offer for shares of common stock of the Issuer (each, a "Share"). After completion of the cash tender offer, Merger Sub merged with and into the Issuer (the "Merger"), effective as of December 27, 2023 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $12.50 in cash (the "Merger Consideration"), without interest and less any applicable tax withholding. A corporation controlled by the Reporting Person. Pursuant to the terms of the Merger Agreement, at the Effective Time, each option (whether vested or unvested) that was outstanding and unexercised immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such option, an amount in cash, without interest, less any applicable tax withholding, equal to the excess, if any, of the Merger Consideration over the exercise price per share of such option. Each option that was outstanding and unexercised immediately prior to the Effective Time which had a per share exercise price greater than or equal to the Merger Consideration was cancelled with no consideration payable. /s/ William L. Demers, by Power of Attorney for Jonathan R. Goodman 2023-12-27